| 2026-08-05 | Presentation | Context Corporate Presentation – August 2026 |
| 2026-08-05 | Press release | Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress |
| 2026-07-10 | Press release | Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-06 | Press release | Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes |
| 2026-06-09 | Press release | Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-27 | Press release | Context Therapeutics to Present at the Jefferies Global Healthcare Conference |
| 2026-05-18 | Press release | Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 |
| 2026-05-06 | Press release | Context Therapeutics Reports First Quarter 2026 Operating and Financial Results |
| 2026-04-02 | Press release | Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovari |
| 2026-03-23 | Press release | Context Therapeutics Reports Full Year 2025 Operating and Financial Results |
| 2025-06-02 | Press release | Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting |
| 2025-04-30 | Press release | Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 20 |
| 2025-03-20 | Press release | Context Therapeutics Reports Full Year 2024 Operating and Financial Results |
| 2024-03-21 | Press release | Context Therapeutics Reports Full Year 2023 Operating and Financial Results |
| 2023-08-01 | Press release | Context Therapeutics to Participate in Two August 2023 Investor Conferences |
| 2023-04-03 | Press release | Context Therapeutics to Participate in Two April 2023 Investor Conferences |
| 2023-03-22 | Press release | Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates |
| 2023-03-15 | Press release | Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (A |
| 2023-01-04 | Press release | Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones |
| 2022-11-21 | Press release | Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium |
| 2022-04-11 | Press release | Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Associati |
| 2022-04-06 | Press release | Context Therapeutics® to Participate in Two April 2022 Investor Conferences |
| 2022-03-23 | Press release | Context Therapeutics® Reports Full Year 2021 Operating and Financial Results |
| 2022-03-08 | Press release | Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Rese |
| 2022-01-04 | Press release | Context Therapeutics® to Participate in Two January 2022 Investor Conferences |
| 2021-12-09 | Press release | Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Sympo |
| 2021-11-19 | Press release | Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium |